Drugs / VI-0106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07612657 | May 2026 → May 2028 expected | pulmonary arterial hypertension | VIVUS LLC | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-10 | VIVUS LLC | VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 vivus.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VI-0106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07612657 ↗ |
| Route | Oral | “1.25 mg or 0.625 mg oral capsules” NCT07612657 ↗ |